Global lung oncology branch trial 3 (GLOB3): Final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer

E. H. Tan*, J. Rolski, T. Grodzki, C. P. Schneider, U. Gatzemeier, P. Zatloukal, E. Aitini, G. Carteni, H. Riska, Y. H. Tsai, R. Abratt

*此作品的通信作者

研究成果: 期刊稿件文章同行評審

58 引文 斯高帕斯(Scopus)

指紋

深入研究「Global lung oncology branch trial 3 (GLOB3): Final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer」主題。共同形成了獨特的指紋。

Nursing and Health Professions

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science